CONMED Corp 8-K

What Happened

• CONMED Corporation announced on January 8, 2026 that Chief Financial Officer Todd W. Garner will separate from his role as CFO effective the earlier of March 15, 2026 or the date a new permanent CFO is appointed (the “CFO Transition Date”).
• Mr. Garner agreed to remain employed through November 2, 2026 (the “Consulting Period”) to support the transition while the company has retained an executive search firm to find his successor. The company says the separation was not due to any disagreement over operations, policies, financial results or accounting practices.

Key Details

• Date announced: January 8, 2026; Letter Agreement dated January 6, 2026.
• Separation effective: earlier of March 15, 2026 or appointment of new permanent CFO; Consulting Period: through November 2, 2026.
• Compensation and benefits: Garner will continue current pay and benefits while CFO through the transition and remain eligible for his 2025 annual bonus to the extent earned; he will not receive a 2026 Q1 annual equity award.
• During the Consulting Period he will receive base salary and may receive a pro‑rated 2026 cash bonus (based on his 2025 target) subject to plan metrics; no 2026 bonus if terminated for “Cause” or if he breaches the agreement/restrictive covenants.
• Severance: Garner will receive severance benefits under CONMED’s Executive Severance Plan in connection with a Qualifying Termination. Outstanding equity awards will continue to vest through November 2, 2026 subject to continued employment and other conditions.

Why It Matters

• A CFO transition is material because it affects financial leadership and reporting continuity; CONMED has arranged for Garner to stay through a consulting period to provide stability while searching for a successor.
• The filing discloses no dispute with management, which reduces potential governance concerns tied to the departure.
• There are no dollar amounts disclosed for severance or costs, but investors should note potential one‑time transition expenses and the timing impact of any new CFO appointment on strategic and financial decisions.